Overview
Starpharma is a Polish contract manufacturer of dietary supplements and a CDMO partner for brands in Poland, Europe and global markets. It develops custom formulations and makes private-label supplements, with more than 400 formulations developed. Its services include GMP-compliant production, quality control, packaging, labelling and regulatory support.
Financials
Revenue history (in m)
Filing timeliness
4 of 6 financial statements were filed late (the longest delay 103 days for 2025). All were audited by a statutory auditor.
- 202526/10/2026
- 202416/09/2025
- 202312/07/2024
- 202206/09/2023
- 202128/09/2022
- 202019/07/2021
Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.
Statistics
How the company ranks by revenue within its industry, region and across Poland in 2025.
Results vs industry
Industry
Trademarks
Starpharma holds 37 active trademarks registered with the Polish Patent Office. 48 marks have expired or were not registered. The first mark was filed in 2001.
| Mark | Protected until | |
|---|---|---|
| LIZIK! | Sep 29, 2035 | |
| Ibu Strong(word) | Aug 7, 2033 | |
| Zdrowy Lizak MNIAM-MNIAM(word) | May 26, 2031 | |
| BIOTINELLA(word) | Jun 19, 2028 | |
| LaciflorStrong | Jun 13, 2028 |
Authorized Representatives
Manner of representation
In the case of a multi-member management board: two members of the management board acting jointly, or a member of the management board jointly with a commercial proxy. In the case of a one-person management board: the only member of the management board.
Ownership
| Owner | Shares | Share value | Stake |
|---|---|---|---|
Path Family Office (suisse) Sa | 1,926 | $260,129.66 | 18.9885% |
| 7,733 | $1,044,435.44 | 76.2398% | |
Others | 484 | $65,370.07 | 4.7717% |
Beneficial owners
| Person | Rights |
|---|---|
Bank accounts
Registered as a VAT taxpayer on 2008-06-01.
27 1050 1025 1000 0090 8328 0199- 15 1050 1025 1000 0090 8013 1213
- 21 1050 1025 1000 0090 3108 0824
Debt
No entries in the National Debtors Register (KRZ).
Real estate
| Type | Amount |
|---|---|
Land (incl. perpetual usufruct) | $326.7K$326,717 |
Buildings and premises | $9.8M$9,769,412 |
Properties named as collateral
Nieruchomość spółki w Lesznowoli | |
Nieruchomość spółki w Lesznowoli, ul. Jedności 9 |
Secured liabilities
| Type | Creditor | |
|---|---|---|
Mortgage | ||
Assignment of receivables | ||
Promissory note |
MSiG notices
| Publication date | Event | |
|---|---|---|
| Apr 3, 2018 | Return of additional payments |
Public aid
20 public aid cases recorded, with a total value of $1,614,765.
| Grant date | Purpose | Gross amount | Granting body | |
|---|---|---|---|---|
| Oct 16, 2026 | Aid for SME participation in trade fairs | –– | Prezes Polskiej Agencji Rozwoju Przedsiębiorczości | |
| Mar 31, 2026 | Regional investment aid | –– | TRZECI MAZOWIECKI URZĄD SKARBOWY W RADOMIU | |
| Nov 25, 2025 | De minimis aid (in accordance with Commission Regulation 2023/2831) | –– | Prezes Banku Gospodarstwa Krajowego |
European Funds
| Start | Project | EU co-financing | Programme | |
|---|---|---|---|---|
| 2020-01-01 | Development of Starpharma Sp. z o.o., affected by the negative effects of Brexit | $27,343$27,343 | Brexit Adjustment Reserve | |
| 2019-04-08 | Implementation of promotional activities by Starpharma as part of the sectoral promotion programme Biotechnology and Pharmaceuticals | $111.2K$111,178 | Operational Programme Smart Growth |
Regulatory authorisations
| Authority | Type | Status | |
|---|---|---|---|
 BDO | BDO register entry | Active |
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| Prosuplement Groupsp. z o.o. | $34,819,545.29 | prosuplement.com | ||
| Efferta Pharmasp. z o.o. | $33,051,786.19 | efferta.pl | ||
| Zakłady Farmaceutyczne ColfarmS.A. | $27,692,749.78 | colfarm.pl | ||
| Global Pharma CmS.A. | $24,132,016.98 | globalpharma.pl | ||
| Master PharmS.A. | $23,116,954.19 | masterpharm.pl | ||
| Symbiofarm Kroksp. k. | $16,922,181.13 | symbiofarm.pl | ||
| Norsa Pharmasp. z o.o. | $9,111,390.60 | norsapharma.eu | ||
| Gofarmsp. z o.o. + limited partnership | $8,632,148.10 | gofarm.pl | ||
| Amerpharmasp. z o.o. | $7,193,674.19 | amerpharma.com | ||
| INV Polandsp. z o.o. | $6,811,226.32 | invpoland.com |
Change history
| Date | Event | |
|---|---|---|
| 2023-09-14 | Address change (Ul. Stawki 2/23 Piętro, 00-193, Warszawa → Jedności 9, 05-506, Lesznowola) | |
| 2022-11-17 | Share capital increase (3,730,000.00 PLN → 5,071,500.00 PLN) | |
| 2018-08-28 | Share capital increase (2,250,000.00 PLN → 3,730,000.00 PLN) | |
| 2017-03-23 | Address change (Dobra 4/10, 00-388, Warszawa → Ul. Stawki 2/23 Piętro, 00-193, Warszawa) | |
| 2016-11-10 | PKD change (Removed: 49 codes) |
FAQ
Last updated: 2026-10-26